Financial Survey: CareDx (CDNA) versus Its Competitors

CareDx (NASDAQ: CDNA) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it weigh in compared to its competitors? We will compare CareDx to related businesses based on the strength of its analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Insider & Institutional Ownership

How to Become a New Pot Stock Millionaire

52.4% of CareDx shares are owned by institutional investors. Comparatively, 53.0% of shares of all “Medical laboratories” companies are owned by institutional investors. 5.4% of CareDx shares are owned by company insiders. Comparatively, 16.9% of shares of all “Medical laboratories” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


This table compares CareDx and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CareDx -114.79% -349.65% -22.88%
CareDx Competitors -110.24% -188.04% -38.52%

Analyst Ratings

This is a breakdown of recent recommendations for CareDx and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx 0 0 4 0 3.00
CareDx Competitors 107 445 522 17 2.41

CareDx presently has a consensus price target of $8.88, suggesting a potential upside of 11.36%. As a group, “Medical laboratories” companies have a potential upside of 16.81%. Given CareDx’s competitors higher possible upside, analysts plainly believe CareDx has less favorable growth aspects than its competitors.

Valuation & Earnings

This table compares CareDx and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CareDx $48.32 million -$55.46 million -10.35
CareDx Competitors $1.13 billion $77.59 million 205.55

CareDx’s competitors have higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

CareDx has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, CareDx’s competitors have a beta of 1.23, indicating that their average stock price is 23% more volatile than the S&P 500.


CareDx competitors beat CareDx on 9 of the 12 factors compared.

CareDx Company Profile

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with's FREE daily email newsletter.

Leave a Reply